Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers

Summary: Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor βγ superagonist that stimulates natural killer (NK) and CD8+ T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in mouse tumor models either in monotherapy or combined with an anti-...

Descripció completa

Dades bibliogràfiques

Autors principals:	Stephane Champiat, Elena Garralda, Vladimir Galvao, Philippe A. Cassier, Carlos Gomez-Roca, Iphigenie Korakis, Peter Grell, Aung Naing, Patricia LoRusso, Romana Mikyskova, Nada Podzimkova, Milan Reinis, Kaissa Ouali, Andreu Schoenenberger, Joachim Kiemle-Kallee, Sascha Tillmanns, Richard Sachse, Ulrich Moebius, Radek Spisek, David Bechard, Lenka Palova Jelinkova, Irena Adkins, Aurelien Marabelle
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-02-01
Col·lecció:	Cell Reports Medicine
Matèries:	nanrilkefusp alfa nanril SOT101 pembrolizumab combination solid tumors anti-tumor efficacy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666379125000400
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!